10-Q: Network-1 Technologies Reports Q3 2024 Results: Revenue Impacted by Litigation Outcomes

Network-1 Technologies reported a net loss for Q3 2024, with revenue significantly impacted by the timing of litigation settlements.

Summary

• Network-1 Technologies reported a net loss of $316,000 for the third quarter of 2024, or $0.01 per share, compared to a net loss of $810,000, or $0.03 per share, for the same period in 2023.
• The company's revenue for the quarter was $0, as no litigation settlements were achieved during the period.
• Operating expenses increased slightly to $896,000 from $859,000 year-over-year, primarily due to higher professional fees.
• Interest and dividend income increased to $524,000 from $406,000 year-over-year, driven by higher yielding fixed income investments.
• The company recorded a net loss of $1,894,000 for the nine months ended September 30, 2024, compared to a net loss of $1,909,000 for the same period in 2023.
• Revenue for the nine months ended September 30, 2024 was $100,000, compared to $820,000 for the same period in 2023, all from litigation settlements related to the Remote Power Patent.
• The company's cash and cash equivalents and marketable securities totaled $41,516,000 as of September 30, 2024.
• The company repurchased 119,615 shares of its common stock at an average price of $1.58 during the three months ended September 30, 2024.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the lack of revenue and continued net losses, although there are some positives such as the improved net loss compared to the previous year and the strong cash position. The uncertainty surrounding litigation outcomes and the investment in ILiAD also contribute to the negative sentiment.

Positives

• The net loss for Q3 2024 was lower than the net loss for Q3 2023.
• Interest and dividend income increased due to higher yielding investments.
• Operating expenses decreased for the nine months ended September 30, 2024 compared to the same period in 2023.
• The company maintains a strong cash position with $41,516,000 in cash and marketable securities.

Negatives

• The company had no revenue in Q3 2024 due to the lack of litigation settlements.
• Revenue for the nine months ended September 30, 2024 was significantly lower than the same period in 2023.
• The company continues to experience net losses.
• The company's equity investment in ILiAD Biotechnologies, LLC resulted in a significant loss.

Risks

• The company's revenue is heavily dependent on the outcome of patent litigation, which is uncertain.
• The company's investment in ILiAD Biotechnologies, LLC is subject to significant risk and the outcome is uncertain.
• The company may be classified as a Personal Holding Company in 2024 or future years, which could result in a 20% tax on undistributed income.
• The company's ability to acquire and monetize new patents is uncertain.
• The company's future operating results may fluctuate significantly due to factors outside of its control.

Future Outlook

The company intends to continue its licensing efforts, monetize its patent portfolios, and seek to acquire additional intellectual property assets. The company also intends to commence efforts to monetize certain patents within its HFT and M2M/IoT patent portfolios. The company's future operating results may be materially impacted by its ability to acquire high quality patents which management believes have the potential to generate significant licensing opportunities.

Management Comments

• The company's revenue is largely dependent upon its ability to achieve successful litigation outcomes.
• The company's investment in ILiAD continues to involve significant risk and the outcome is uncertain.
• The company has been dependent upon its Remote Power Patent for a significant portion of its revenue.
• The company may not achieve successful outcomes of appeals or litigation involving its patent assets.

Industry Context

The company operates in the intellectual property licensing and enforcement industry, which is characterized by high uncertainty and dependence on litigation outcomes. The company's focus on acquiring high-quality patents with significant licensing potential is a common strategy in this industry. The company's investment in a biotechnology company is a diversification strategy that is not typical for companies in this sector.

Comparison to Industry Standards

• Network-1's reliance on patent litigation for revenue is typical of companies in the intellectual property licensing sector, but the lack of revenue in Q3 2024 highlights the volatility of this model.
• Compared to companies like Acacia Research or Marathon Patent Group, Network-1's revenue is significantly lower this quarter, reflecting the unpredictable nature of litigation outcomes.
• The company's investment in ILiAD is unusual for a patent licensing company, as most focus on acquiring and monetizing patents, not investing in biotechnology.
• The company's cash position is relatively strong compared to some smaller players in the industry, providing a buffer against the volatility of litigation outcomes.

Legal Proceedings

• The company is awaiting a decision on the appeal of the Meta (Facebook) litigation.
• The company is pursuing litigation against Ubiquiti Inc. regarding the Remote Power Patent.
• The company has appealed the judgment of the District Court dismissing its litigation against Google and YouTube.
• A putative class action against the company and its Chairman and CEO was settled and withdrawn on October 3, 2024.

Stakeholder Impact

• Shareholders are impacted by the net losses and the uncertainty surrounding the company's future revenue.
• Employees are impacted by the company's financial performance and the potential for changes in strategy.
• Customers are not directly impacted as the company does not sell products or services.
• Suppliers are not directly impacted as the company does not have significant supply chain operations.
• Creditors are not directly impacted as the company has no long-term debt.

Next Steps

• The company intends to continue its licensing efforts with respect to its intellectual property assets.
• The company intends to continue to seek to acquire additional intellectual property assets to develop, commercialize, license or otherwise monetize.
• The company intends to commence efforts to monetize certain patents within its HFT and M2M/IoT patent portfolios.
• The company is awaiting a decision on the appeal of the Meta (Facebook) litigation.
• The company will continue to pursue litigation against Ubiquiti Inc. regarding the Remote Power Patent.

Key Dates

Keywords

patent licensing, intellectual property, litigation, Remote Power Patent, M2M/IoT, HFT, Mirror Worlds, financial results, stock repurchase, ILiAD Biotechnologies